TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06555328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSU lower dose treatment
Description: CSU lower dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSU high dose treatment
Description: CSU high dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSU non responders IgE - high dose treatment
Description: CSU non responders IgE - high dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS low dose treatment
Description: HS low dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS medium dose treatment
Description: HS medium dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS high dose treatment
Description: HS high dose treatment
Study: NCT04757194

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: openTriage - Alitis algorithm
Description: A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
Study: NCT06372145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT05010772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04495959

Intervention type: DRUG
Intervention: 68Ga-HTK03149
Description: PET/MRI scan with radiotracer 68Ga-HTK03149
Study: NCT06484309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflexology Group
Description: * In the 3rd stage of labor, local anesthesia (5 ml lidocaine 2%) will be applied and episiotomy repair will begin.~* Reflexology application will be started at the same time,~* Reflexology application will continue for at least 20-30 minutes during the episiotomy repair until the episiotomy repair is completed,~* Pain will be evaluated with VAS to determine the pain level four times in total: just before suturing, during perineal suturing (internal), during skin suturing and immediately after suturing is completed,~* Approximately 15-20 minutes after the end of the episiotomy repair, a face-to-face interview will be held and the McGill Pain Questionnaire will be filled out.
Study: NCT06130358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Well-being intervention followed by classic intervention
Description: 2 x 6 weeks of weekly museum visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Well-being intervention followed by classic intervention
Description: 2 x 6 weeks of weekly museum visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Classic intervention followed by well-being intervention
Description: 2 x 6 weeks of weekly museum visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Classic intervention followed by well-being intervention
Description: 2 x 6 weeks of weekly museum visits
Study: NCT03538236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation A SC
Description: Low (\<1mL) starting dose of VH4524184 LAI Formulation A administered subcutaneously.
Study: NCT06161116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: SC Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: SC Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: SC Injection
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation A SC
Description: Low (\<1mL) starting dose of VH4524184 LAI Formulation A administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation A SC
Description: Starting dose of Placebo Formulation A administered subcutaneously.
Study: NCT06161116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: SC Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC Injection
Study: NCT06012708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 60mg/day + KN713 60mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 120mg/day + KN713 60mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 120mg/day + KN713 90mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 120mg/day + KN713 120mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.
Study: NCT04632953

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05090800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity contrast during ultrasound
Description: Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
Study: NCT03799991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular physical therapy
Description: Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation A SC
Description: Starting dose of Placebo Formulation A administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Dose of rHuPH20 administered subcutaneously.
Study: NCT03799991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Strength and flexibility exercises that do not involve head movements.
Study: NCT05999383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana in varying doses from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana in varying doses from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana in varying doses from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana in varying doses from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana in varying doses from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Dose of rHuPH20 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Dose of rHuPH20 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Dose of rHuPH20 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation B SC
Description: Starting dose of VH4524184 LAI Formulation B administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation B SC
Description: Starting dose of VH4524184 LAI Formulation B administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation B SC
Description: Starting dose of Placebo Formulation B administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation B SC
Description: Starting dose of Placebo Formulation B administered subcutaneously.
Study: NCT05999383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation C SC
Description: Starting dose of VH4524184 LAI Formulation C administered subcutaneously.
Study: NCT05999383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pax Loose Leaf Vaporizer
Description: In all arms, participants will be using the PAX Loose Leave Vaporizer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Marijuana
Description: Participants will vape placebo marijuana from the PAX device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Marijuana
Description: Participants will vape placebo marijuana from the PAX device
Study: NCT03929952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment
Description: 20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging (fMRI) scans
Description: The patient in alpha synchrony related state and in rating state will undergo an fMRI
Study: NCT06065540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation C SC
Description: Starting dose of VH4524184 LAI Formulation C administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation C SC
Description: Dose of Placebo Formulation C administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation C SC
Description: Dose of Placebo Formulation C administered subcutaneously.
Study: NCT06065540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation A IM
Description: Starting dose VH4524184 LAI Formulation A administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation A IM
Description: Starting dose VH4524184 LAI Formulation A administered intramuscularly.
Study: NCT06065540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide subcutaneously.
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation A IM
Description: Dose of Placebo Formulation A administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation A IM
Description: Dose of Placebo Formulation A administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation B IM
Description: Starting dose VH4524184 LAI Formulation B administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation B IM
Description: Starting dose VH4524184 LAI Formulation B administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation B IM
Description: Dose of Placebo Formulation B administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation B IM
Description: Dose of Placebo Formulation B administered intramuscularly.
Study: NCT04950270

Intervention type: BIOLOGICAL
Intervention: Blood copeptin monitoring
Description: Blood copeptin monitoring during the first 6 days of ICU stay with PRES

Intervention type: OTHER
Intervention: phone interview
Description: Structured phone interview at 3 months to collect vital status and modified Rankin Scale score
Study: NCT05905653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
Study: NCT05055297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR™ DEB 014
Description: a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain (Uncoated) Balloon Angioplasty (PTA)
Description: a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
Study: NCT05093634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT04719273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Onapristone
Description: Given PO
Study: NCT05303922

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy CT
Description: Dual-energy CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI
Study: NCT05119322

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GlutenDetect home urine test
Description: GFD compliance self-asessment using a home rapid test for GIP detection in urine.
Study: NCT04752592

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SeroSelectTB rapid TB test
Description: The SeroSelectTB test is a rapid blood-based immunochemical lateral flow assay for the detection of active tuberculosis.
Study: NCT02446210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim 200
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim 200
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digitimer electrical stimulator
Description: Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digitimer electrical stimulator
Description: Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation